title: Intravitreal bevacizumab for choroidal neovascularisation secondary to punctate inner choroidopathy.
authors.forename: Urs
authors.initials: U
authors.lastname: Vossmerbaeumer
authors.forename: Ulrich H M
authors.initials: UH
authors.lastname: Spandau
authors.forename: Stefan
authors.initials: S
authors.lastname: V Baltz
authors.forename: Anne
authors.initials: A
authors.lastname: Wickenhaeuser
authors.forename: Jost B
authors.initials: JB
authors.lastname: Jonas
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D002833:Choroiditis / Q000150:complications* / Q000175:diagnosis; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab